Publications by authors named "Evy Ulijn"
Article Synopsis
- The study investigated the prevalence and significance of RA-associated erosions in newly presenting arthritis patients suspected of rheumatoid arthritis (RA) using routine X-rays of hands and feet (X-HF).
- The results showed that erosions were found in only 4.4% of the 724 patients, with minimal influence on diagnosis (change in 0.3% of cases) and prognosis (change in 0.4% of cases).
- Ultimately, the low prevalence and limited impact on diagnostic and prognostic classifications suggest reconsidering the routine use of X-HF in such patients.
Objectives: To quantify the additional value of a hypothetical biomarker predicting response to treatment for RA regarding efficacy and costs by using a modelling design.
Methods: A Markov model was built comparing a usual care T2T strategy with a biomarker-steered strategy for RA patients starting biologic therapy. Outcome measures include time spent in remission or low disease activity (LDA) and costs.
Objective: Whole-body PET with CT scanning using F-fluorodeoxyglucose (F-FDG) is used occasionally in RA patients to detect arthritis. FDG-PET/CT might also detect malignancies, but the amount of incidental findings and the number of relevant malignant diseases that could be missed are currently unknown. We aimed to study the malignancy screening performance of whole-body FDG-PET/CT in longstanding RA patients with low disease activity.
View Article and Find Full Text PDFBackground: After adalimumab treatment failure, tumour necrosis factor inhibition (TNFi) and non-TNFi biological disease-modifying anti-rheumatic drugs (bDMARDs) are equally viable options on a group level as subsequent treatment in rheumatoid arthritis (RA) based on the current best evidence synthesis. However, preliminary data suggest that anti-adalimumab antibodies (anti-drug antibodies, ADA) and adalimumab serum levels (ADL) during treatment predict response to a TNFi as subsequent treatment.
Objective: To validate the association of presence of ADA and/or low ADL with response to a subsequent TNFi bDMARD or non-TNFi bDMARD.